Find your next paid study

Advenchen Pharmaceuticals, LLC.NCT07811232

Endometrial NeoplasmsOvarian NeoplasmsSoft Tissue Sarcoma (STS)+1 more

Phase 1b/2a Clinical Study of Catequentinib Hydrochloride (AL3818) Monotherapy or Combining Therapy With Other Anti-tumor Agents in Advanced, Metastatic Endometrial, Low Grade Serous Ovarian Cancer (LGSOC), STS or GBM Cancers

This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (C…

Advenchen Pharmaceuticals, LLC.NCT07811297

Observational

Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention

This study will evaluate strategies to improve physical function and promote exercise and physical activity in adolescents and young adults (AYAs) with sarcoma…

SarcomaBone SarcomaSoft Tissue Sarcoma (STS)

Dana-Farber Cancer InstituteNCT07662239

~$10 – $7,500

Soft Tissue Sarcoma (STS)

5-AminoLevulinic Acid Aided Resection Margins in Sarcoma (5-ALARMS)

The goal of this study is to learn if the intervention using a fluorescent agent 5-Aminolevulinic acid (5-ALA) to aid in the surgical approach to visualize the…

University of Colorado, DenverNCT07038278

~$10 – $6,250

Epithelial Ovarian CancerGastro-esophageal Junction CancerSoft Tissue Sarcoma (STS)+2 more

EPITOME-1015-I: a Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of a Third Generation TCR-T Therapy, MDG1015, in Epithelial Ovarian Carcinoma, Gastroesophageal (Junction) Adenocarcinoma, Myxoid (Round Cell) Liposarcoma And/or Synovial Sarcoma Subjects with Advanced Disease Expressing NY-ESO-1 And/or LAGE-1a

MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP). The stu…

Medigene AGNCT06748872

Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination wi…